SlideShare a Scribd company logo
1 of 39
CANCER IN WOMEN
2009 Estimated US Cancer Cases*


                                           Men               Women
                                          766,130            713,220
Prostate                      25%                                            27%       Breast
Lung & bronchus               15%                                            14%       Lung & bronchus
Colon & rectum                10%                                            10%       Colon & rectum
Urinary bladder                7%                                             6%       Uterine corpus
Melanoma of skin               5%                                             4%       Non-Hodgkin
                                                                                         lymphoma
Non-Hodgkin                    5%
   lymphoma                                                                   4%       Melanoma of skin
Kidney & renal pelvis          5%                                             4%       Thyroid
Leukemia                       3%                                             3%       Kidney & renal pelvis
Oral cavity                    3%                                             3%       Ovary
Pancreas                       3%                                             3%       Pancreas
All Other Sites               19%                                            22%       All Other Sites



*Excludes basal and squamous cell skin cancers and in situ carcinomas except urinary bladder.
Source: American Cancer Society, 2009.
2009 Estimated US Cancer Deaths*



                                          Men      26%   Lung & bronchus
Lung & bronchus             30%
                                         292,540   15%   Breast
Prostate                      9%
                                                   9%    Colon & rectum
Colon & rectum                9%
                                                   6%    Pancreas
Pancreas                      6%
                                                   5%    Ovary
Leukemia                      4%
                                                   4%    Non-Hodgkin
Liver & intrahepatic          4%                          lymphoma
    bile duct
                                                   3%
Esophagus                     4%
                                                   3%    Uterine corpus
Urinary bladder               3%
                                                   2%     Liver & intrahepatic
Non-Hodgkin                  3%                                        bile duct
   lymphoma                                                      Women
                                                   2%    Brain/ONS &
                                                                 269,800
Kidney & renal pelvis         3%
                                                   25%   All other sites
All other sites             25%



ONS=Other nervous system.
Source: American Cancer Society, 2009.
Cancer Death Rates* Among Women, US,1930-2005



100
             Rate Per 100,000


 80



 60


                                                                                                            Lung & bronchus
 40          Uterus
                                                                       Breast


                                                            Colon & rectum
 20                   Stomach


                      Ovary

                                                                 Pancreas
  0
      1930


               1935


                         1940


                                1945


                                       1950


                                              1955


                                                     1960


                                                                1965


                                                                        1970


                                                                                1975


                                                                                       1980


                                                                                              1985


                                                                                                     1990


                                                                                                              1995


                                                                                                                     2000


                                                                                                                            2005
 *Age-adjusted to the 2000 US standard population.
 Source: US Mortality Data 1960-2005, US Mortality Volumes 1930-1959,
 National Center for Health Statistics, Centers for Disease Control and Prevention, 2008.
VULVAR CANCER
Where does it come from?

 Age
 Squamous cell 90%
 HPV
   Sex
   Tobacco
 Chronic
   conditions
How does it act?

 Symptoms
 Progression
 Spread
   Local
   Lymphatic
   Ipsilateral
Diagnosis

Ears

Eyes

Biopsy
Treatment

 Remove it
   No invasion or < 1mm EXCISION
   >1mm invasion
     Node dissection
   Positive nodes
     Radiation
   Large bulky lesion
     Radiate first
A Sexually transmitted disease

CERVICAL CANCER
Who gets it?

 99% of squamous cell cervical cancers have
  high- risk HPV subtypes

 Tobacco increases risk 3.5% 0ver non-
  smokers

 Immunosuppression

 Symptoms= PC spotting , irreg bleeding
How does it behave?

 Step-wise from atypia > LGSIL> HGSIL>
  Carcinoma
 Rate of progression
 Local to Lymphatic
Prevention=
   Behavior
Screening

 Good sample
 Accuracy
 HPV testing
Bethesda System

 Normal
 Atypical
   ASCUS
 Squamous Intraepithelial Lesion (SIL)
   Low-grade
   High-grade
 Atypical glandular cells
 Endometrial cells found
How do we diagnose it?

Ears

Screening (Pap Smear)

Eyes (colposcopy)

Biopsy
Treatment

 Destruction
   Cryotherapy
   Laser
 Excision
   Laser
   LEEP
   Surgery


   How to decide?
Other issues

Associated cancers
  oral
  anal

Lesbian health
  Large percentage / hx of sexual contact with
  men
                ASK !!!!!
ENDOMETRIAL CANCER
Basic Information

 Age (average = 60 y/o)


 Etiology


 Progresses from normal through increasing
  levels of abnormal cell changes to cancer

 Histology
Risk factors

 Estrogen stimulation (unopposed or inadequately
  opposed)
     Nulliparity
     Infertility
     PCOS
     Irregular menses
     Elevated BMI
 Time
   Early menarche
   Late menopause ( after age 52)
   Increasing age
 Genetics
how to find it….

Screening      Symptoms
 None          Post menopausal bleeding

                Abnormal perimenopausal
                    bleeding


PHYSICAL       DIAGNOSIS

 normal        Endometrial biopsy
Tissue Diagnosis

 Aspiration biopsy
   Agrees with pathology 98% of the time
 D&C
   OP
   Can still miss the worst areas
 Hysterectomy
   Ultimate diagnosis
   Treatment for early stage lesions
Ultrasound


              f= fundus


              Cx= cervix


              Arrows point to outer
               edges of endometrium

              Thin line in the middle is
               the uterine cavity
Behavior

 Local


 Lymphatic



 Cancerfacts.com
   (view video from this link and scroll down to the
    pictures to see the normal progression)
Treatment

 Reverse
  Progestational agents

 Remove
  Surgery

 Radiate
  Local
  Pelvic
  Pelvic and periaortic
Prognosis

Common cell types? GOOD
 earlier the better
 adequate staging = adequate treatment
 follow-up easily performed

Rare cell types? NOT SO GOOD
  Papillary serous
  Sarcoma
  Mixed Muellerian tumors, etc
Synopsis

           LISTEN!!!!
              Is she at risk?
             Is there abnormal bleeding?

         LOOK!!
       No screening
       No xrays
       No labs
          *BIOPSY*
OVARIAN CANCER
Who gets it?

 Average age = 63
 Nulliparous
 Infertility
 Endometriosis
 Genetic predisposition
   BRCA 1 & BRCA 2
   Lynch II (associated with colon and breast ca)
 High Fat diet
Prevention (< risk)

 Oral contraceptives
 Breast feeding
 Hysterectomy
 Tubal ligation
Symptoms/ Screening

                Bloating
                Constipation
                Abdominal discomfort
                Indigestion
                Urinary incontinence
                Urinary frequency
                Fatigue
                Anything that doesn’t
                 feel right in the abdomen
How does it behave?

 Cell types
 85% epithelial
     Benign
     Low malignant
           potential
     Malignant
Local
Lymphatic
Exfoliates
Treatment

 Bad News                   Even more….
   2/3 have advanced          May develop resistance
    disease when diagnosed     to the chemo before 1st
   Tx: Surgical debulking     tx over
    (cytoreduction)
 More bad news
                             Death
   Chemotherapy next
   With advanced disease      Bowel obstruction
    only 50 % remission        malnutrition
    after chemo
                               Ureteral obstruction

More Related Content

Similar to Cancer

neoplastic disruptions
neoplastic disruptionsneoplastic disruptions
neoplastic disruptionstwiggypiggy
 
Pakistan Oncology Update
Pakistan Oncology UpdatePakistan Oncology Update
Pakistan Oncology UpdateKhurram Khan
 
Am 11.30 grunfeld
Am 11.30 grunfeldAm 11.30 grunfeld
Am 11.30 grunfeldplmiami
 
2009 Cancer Statistics
2009 Cancer Statistics2009 Cancer Statistics
2009 Cancer Statisticscmurray
 
Denjoy, Nicole - The importante of innovative technologies in healthcare. COC...
Denjoy, Nicole - The importante of innovative technologies in healthcare. COC...Denjoy, Nicole - The importante of innovative technologies in healthcare. COC...
Denjoy, Nicole - The importante of innovative technologies in healthcare. COC...ponencias_mihealth2012
 
Cancer estadisticas-Dr peñaloza
Cancer estadisticas-Dr peñalozaCancer estadisticas-Dr peñaloza
Cancer estadisticas-Dr peñalozaClinica de imagenes
 
CES202002 - 08 - Cáncer de colon y recto
CES202002 - 08 - Cáncer de colon y rectoCES202002 - 08 - Cáncer de colon y recto
CES202002 - 08 - Cáncer de colon y rectoMauricio Lema
 
The Epidemic of Thyroid Nodules: Which Should Undergo Fine Needle Aspiration?
The Epidemic of Thyroid Nodules: Which Should Undergo Fine Needle Aspiration?The Epidemic of Thyroid Nodules: Which Should Undergo Fine Needle Aspiration?
The Epidemic of Thyroid Nodules: Which Should Undergo Fine Needle Aspiration?u.surgery
 
Estadísticas del Cáncer: Un análisis detallado sobre su incidencia y impacto ...
Estadísticas del Cáncer: Un análisis detallado sobre su incidencia y impacto ...Estadísticas del Cáncer: Un análisis detallado sobre su incidencia y impacto ...
Estadísticas del Cáncer: Un análisis detallado sobre su incidencia y impacto ...FabrizzioJamancaAgue
 
Rodent liver tumors - Japan.pptx
Rodent liver tumors - Japan.pptxRodent liver tumors - Japan.pptx
Rodent liver tumors - Japan.pptxJeremy Maronpot
 
colon cancer 2022.pptx
colon cancer 2022.pptxcolon cancer 2022.pptx
colon cancer 2022.pptxNawrsHasan
 
Breast Cancer in Lebanon: overview and statistical data
Breast Cancer in Lebanon: overview and statistical dataBreast Cancer in Lebanon: overview and statistical data
Breast Cancer in Lebanon: overview and statistical dataNajla El Bizri
 

Similar to Cancer (20)

Rectal CA pp
Rectal CA ppRectal CA pp
Rectal CA pp
 
Overview of Utah Cancer Incidence and Mortality
Overview of Utah Cancer Incidence and MortalityOverview of Utah Cancer Incidence and Mortality
Overview of Utah Cancer Incidence and Mortality
 
neoplastic disruptions
neoplastic disruptionsneoplastic disruptions
neoplastic disruptions
 
Cervical Cancer
Cervical CancerCervical Cancer
Cervical Cancer
 
Pakistan Oncology Update
Pakistan Oncology UpdatePakistan Oncology Update
Pakistan Oncology Update
 
Am 11.30 grunfeld
Am 11.30 grunfeldAm 11.30 grunfeld
Am 11.30 grunfeld
 
The Second Annual Early Age Onset Colorectal Cancer Summit
The Second Annual Early Age Onset Colorectal Cancer SummitThe Second Annual Early Age Onset Colorectal Cancer Summit
The Second Annual Early Age Onset Colorectal Cancer Summit
 
2009 Cancer Statistics
2009 Cancer Statistics2009 Cancer Statistics
2009 Cancer Statistics
 
Denjoy, Nicole - The importante of innovative technologies in healthcare. COC...
Denjoy, Nicole - The importante of innovative technologies in healthcare. COC...Denjoy, Nicole - The importante of innovative technologies in healthcare. COC...
Denjoy, Nicole - The importante of innovative technologies in healthcare. COC...
 
Esophagus cancer
Esophagus cancerEsophagus cancer
Esophagus cancer
 
Cancer Statistics 2006 Presentation
Cancer Statistics 2006 PresentationCancer Statistics 2006 Presentation
Cancer Statistics 2006 Presentation
 
Carcinoma endometrium
Carcinoma endometriumCarcinoma endometrium
Carcinoma endometrium
 
Cancer estadisticas-Dr peñaloza
Cancer estadisticas-Dr peñalozaCancer estadisticas-Dr peñaloza
Cancer estadisticas-Dr peñaloza
 
CES202002 - 08 - Cáncer de colon y recto
CES202002 - 08 - Cáncer de colon y rectoCES202002 - 08 - Cáncer de colon y recto
CES202002 - 08 - Cáncer de colon y recto
 
The Epidemic of Thyroid Nodules: Which Should Undergo Fine Needle Aspiration?
The Epidemic of Thyroid Nodules: Which Should Undergo Fine Needle Aspiration?The Epidemic of Thyroid Nodules: Which Should Undergo Fine Needle Aspiration?
The Epidemic of Thyroid Nodules: Which Should Undergo Fine Needle Aspiration?
 
Estadísticas del Cáncer: Un análisis detallado sobre su incidencia y impacto ...
Estadísticas del Cáncer: Un análisis detallado sobre su incidencia y impacto ...Estadísticas del Cáncer: Un análisis detallado sobre su incidencia y impacto ...
Estadísticas del Cáncer: Un análisis detallado sobre su incidencia y impacto ...
 
Rodent liver tumors - Japan.pptx
Rodent liver tumors - Japan.pptxRodent liver tumors - Japan.pptx
Rodent liver tumors - Japan.pptx
 
colon cancer 2022.pptx
colon cancer 2022.pptxcolon cancer 2022.pptx
colon cancer 2022.pptx
 
Breast Cancer in Lebanon: overview and statistical data
Breast Cancer in Lebanon: overview and statistical dataBreast Cancer in Lebanon: overview and statistical data
Breast Cancer in Lebanon: overview and statistical data
 
Athira
Athira Athira
Athira
 

More from mrhaakgyn

Textfor introtowomenshealth
Textfor introtowomenshealthTextfor introtowomenshealth
Textfor introtowomenshealthmrhaakgyn
 
Introduction to women’s health/slides
Introduction to women’s health/slidesIntroduction to women’s health/slides
Introduction to women’s health/slidesmrhaakgyn
 
Endometrial Cancer
Endometrial CancerEndometrial Cancer
Endometrial Cancermrhaakgyn
 
Pms And Pmdd 2010
Pms And Pmdd 2010Pms And Pmdd 2010
Pms And Pmdd 2010mrhaakgyn
 

More from mrhaakgyn (7)

Health
HealthHealth
Health
 
Rei part ii
Rei  part iiRei  part ii
Rei part ii
 
Rei part i
Rei part iRei part i
Rei part i
 
Textfor introtowomenshealth
Textfor introtowomenshealthTextfor introtowomenshealth
Textfor introtowomenshealth
 
Introduction to women’s health/slides
Introduction to women’s health/slidesIntroduction to women’s health/slides
Introduction to women’s health/slides
 
Endometrial Cancer
Endometrial CancerEndometrial Cancer
Endometrial Cancer
 
Pms And Pmdd 2010
Pms And Pmdd 2010Pms And Pmdd 2010
Pms And Pmdd 2010
 

Recently uploaded

Activity 2-unit 2-update 2024. English translation
Activity 2-unit 2-update 2024. English translationActivity 2-unit 2-update 2024. English translation
Activity 2-unit 2-update 2024. English translationRosabel UA
 
Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)Mark Reed
 
ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4MiaBumagat1
 
Transaction Management in Database Management System
Transaction Management in Database Management SystemTransaction Management in Database Management System
Transaction Management in Database Management SystemChristalin Nelson
 
Active Learning Strategies (in short ALS).pdf
Active Learning Strategies (in short ALS).pdfActive Learning Strategies (in short ALS).pdf
Active Learning Strategies (in short ALS).pdfPatidar M
 
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptxMULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptxAnupkumar Sharma
 
Daily Lesson Plan in Mathematics Quarter 4
Daily Lesson Plan in Mathematics Quarter 4Daily Lesson Plan in Mathematics Quarter 4
Daily Lesson Plan in Mathematics Quarter 4JOYLYNSAMANIEGO
 
Earth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice greatEarth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice greatYousafMalik24
 
4.18.24 Movement Legacies, Reflection, and Review.pptx
4.18.24 Movement Legacies, Reflection, and Review.pptx4.18.24 Movement Legacies, Reflection, and Review.pptx
4.18.24 Movement Legacies, Reflection, and Review.pptxmary850239
 
Q4-PPT-Music9_Lesson-1-Romantic-Opera.pptx
Q4-PPT-Music9_Lesson-1-Romantic-Opera.pptxQ4-PPT-Music9_Lesson-1-Romantic-Opera.pptx
Q4-PPT-Music9_Lesson-1-Romantic-Opera.pptxlancelewisportillo
 
Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Celine George
 
Global Lehigh Strategic Initiatives (without descriptions)
Global Lehigh Strategic Initiatives (without descriptions)Global Lehigh Strategic Initiatives (without descriptions)
Global Lehigh Strategic Initiatives (without descriptions)cama23
 
ISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITY
ISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITYISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITY
ISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITYKayeClaireEstoconing
 
4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptx4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptxmary850239
 
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...Postal Advocate Inc.
 
Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Celine George
 
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdfGrade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdfJemuel Francisco
 
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17Celine George
 

Recently uploaded (20)

Activity 2-unit 2-update 2024. English translation
Activity 2-unit 2-update 2024. English translationActivity 2-unit 2-update 2024. English translation
Activity 2-unit 2-update 2024. English translation
 
Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)
 
Raw materials used in Herbal Cosmetics.pptx
Raw materials used in Herbal Cosmetics.pptxRaw materials used in Herbal Cosmetics.pptx
Raw materials used in Herbal Cosmetics.pptx
 
ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4
 
Transaction Management in Database Management System
Transaction Management in Database Management SystemTransaction Management in Database Management System
Transaction Management in Database Management System
 
Active Learning Strategies (in short ALS).pdf
Active Learning Strategies (in short ALS).pdfActive Learning Strategies (in short ALS).pdf
Active Learning Strategies (in short ALS).pdf
 
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptxMULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
 
Daily Lesson Plan in Mathematics Quarter 4
Daily Lesson Plan in Mathematics Quarter 4Daily Lesson Plan in Mathematics Quarter 4
Daily Lesson Plan in Mathematics Quarter 4
 
LEFT_ON_C'N_ PRELIMS_EL_DORADO_2024.pptx
LEFT_ON_C'N_ PRELIMS_EL_DORADO_2024.pptxLEFT_ON_C'N_ PRELIMS_EL_DORADO_2024.pptx
LEFT_ON_C'N_ PRELIMS_EL_DORADO_2024.pptx
 
Earth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice greatEarth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice great
 
4.18.24 Movement Legacies, Reflection, and Review.pptx
4.18.24 Movement Legacies, Reflection, and Review.pptx4.18.24 Movement Legacies, Reflection, and Review.pptx
4.18.24 Movement Legacies, Reflection, and Review.pptx
 
Q4-PPT-Music9_Lesson-1-Romantic-Opera.pptx
Q4-PPT-Music9_Lesson-1-Romantic-Opera.pptxQ4-PPT-Music9_Lesson-1-Romantic-Opera.pptx
Q4-PPT-Music9_Lesson-1-Romantic-Opera.pptx
 
Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17
 
Global Lehigh Strategic Initiatives (without descriptions)
Global Lehigh Strategic Initiatives (without descriptions)Global Lehigh Strategic Initiatives (without descriptions)
Global Lehigh Strategic Initiatives (without descriptions)
 
ISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITY
ISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITYISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITY
ISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITY
 
4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptx4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptx
 
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...
 
Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17
 
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdfGrade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
 
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
 

Cancer

  • 2. 2009 Estimated US Cancer Cases* Men Women 766,130 713,220 Prostate 25% 27% Breast Lung & bronchus 15% 14% Lung & bronchus Colon & rectum 10% 10% Colon & rectum Urinary bladder 7% 6% Uterine corpus Melanoma of skin 5% 4% Non-Hodgkin lymphoma Non-Hodgkin 5% lymphoma 4% Melanoma of skin Kidney & renal pelvis 5% 4% Thyroid Leukemia 3% 3% Kidney & renal pelvis Oral cavity 3% 3% Ovary Pancreas 3% 3% Pancreas All Other Sites 19% 22% All Other Sites *Excludes basal and squamous cell skin cancers and in situ carcinomas except urinary bladder. Source: American Cancer Society, 2009.
  • 3. 2009 Estimated US Cancer Deaths* Men 26% Lung & bronchus Lung & bronchus 30% 292,540 15% Breast Prostate 9% 9% Colon & rectum Colon & rectum 9% 6% Pancreas Pancreas 6% 5% Ovary Leukemia 4% 4% Non-Hodgkin Liver & intrahepatic 4% lymphoma bile duct 3% Esophagus 4% 3% Uterine corpus Urinary bladder 3% 2% Liver & intrahepatic Non-Hodgkin 3% bile duct lymphoma Women 2% Brain/ONS & 269,800 Kidney & renal pelvis 3% 25% All other sites All other sites 25% ONS=Other nervous system. Source: American Cancer Society, 2009.
  • 4. Cancer Death Rates* Among Women, US,1930-2005 100 Rate Per 100,000 80 60 Lung & bronchus 40 Uterus Breast Colon & rectum 20 Stomach Ovary Pancreas 0 1930 1935 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 *Age-adjusted to the 2000 US standard population. Source: US Mortality Data 1960-2005, US Mortality Volumes 1930-1959, National Center for Health Statistics, Centers for Disease Control and Prevention, 2008.
  • 6. Where does it come from?  Age  Squamous cell 90%  HPV  Sex  Tobacco  Chronic  conditions
  • 7. How does it act?  Symptoms  Progression  Spread  Local  Lymphatic  Ipsilateral
  • 8.
  • 10. Treatment  Remove it  No invasion or < 1mm EXCISION  >1mm invasion  Node dissection  Positive nodes  Radiation  Large bulky lesion  Radiate first
  • 11.
  • 12. A Sexually transmitted disease CERVICAL CANCER
  • 13. Who gets it?  99% of squamous cell cervical cancers have high- risk HPV subtypes  Tobacco increases risk 3.5% 0ver non- smokers  Immunosuppression  Symptoms= PC spotting , irreg bleeding
  • 14. How does it behave?  Step-wise from atypia > LGSIL> HGSIL> Carcinoma  Rate of progression  Local to Lymphatic
  • 15. Prevention= Behavior
  • 16. Screening  Good sample  Accuracy  HPV testing
  • 17. Bethesda System  Normal  Atypical  ASCUS  Squamous Intraepithelial Lesion (SIL)  Low-grade  High-grade  Atypical glandular cells  Endometrial cells found
  • 18. How do we diagnose it? Ears Screening (Pap Smear) Eyes (colposcopy) Biopsy
  • 19. Treatment  Destruction  Cryotherapy  Laser  Excision  Laser  LEEP  Surgery  How to decide?
  • 20. Other issues Associated cancers oral anal Lesbian health Large percentage / hx of sexual contact with men ASK !!!!!
  • 21.
  • 23. Basic Information  Age (average = 60 y/o)  Etiology  Progresses from normal through increasing levels of abnormal cell changes to cancer  Histology
  • 24. Risk factors  Estrogen stimulation (unopposed or inadequately opposed)  Nulliparity  Infertility  PCOS  Irregular menses  Elevated BMI  Time  Early menarche  Late menopause ( after age 52)  Increasing age  Genetics
  • 25. how to find it…. Screening Symptoms  None  Post menopausal bleeding  Abnormal perimenopausal bleeding PHYSICAL DIAGNOSIS  normal  Endometrial biopsy
  • 26. Tissue Diagnosis  Aspiration biopsy  Agrees with pathology 98% of the time  D&C  OP  Can still miss the worst areas  Hysterectomy  Ultimate diagnosis  Treatment for early stage lesions
  • 27. Ultrasound  f= fundus  Cx= cervix  Arrows point to outer edges of endometrium  Thin line in the middle is the uterine cavity
  • 28. Behavior  Local  Lymphatic  Cancerfacts.com  (view video from this link and scroll down to the pictures to see the normal progression)
  • 29. Treatment  Reverse  Progestational agents  Remove  Surgery  Radiate  Local  Pelvic  Pelvic and periaortic
  • 30. Prognosis Common cell types? GOOD earlier the better adequate staging = adequate treatment follow-up easily performed Rare cell types? NOT SO GOOD Papillary serous Sarcoma Mixed Muellerian tumors, etc
  • 31. Synopsis LISTEN!!!! Is she at risk? Is there abnormal bleeding? LOOK!! No screening No xrays No labs *BIOPSY*
  • 32.
  • 34.
  • 35. Who gets it?  Average age = 63  Nulliparous  Infertility  Endometriosis  Genetic predisposition  BRCA 1 & BRCA 2  Lynch II (associated with colon and breast ca)  High Fat diet
  • 36. Prevention (< risk)  Oral contraceptives  Breast feeding  Hysterectomy  Tubal ligation
  • 37. Symptoms/ Screening  Bloating  Constipation  Abdominal discomfort  Indigestion  Urinary incontinence  Urinary frequency  Fatigue  Anything that doesn’t feel right in the abdomen
  • 38. How does it behave?  Cell types  85% epithelial Benign Low malignant potential Malignant Local Lymphatic Exfoliates
  • 39. Treatment  Bad News Even more….  2/3 have advanced May develop resistance disease when diagnosed to the chemo before 1st  Tx: Surgical debulking tx over (cytoreduction)  More bad news Death  Chemotherapy next  With advanced disease Bowel obstruction only 50 % remission malnutrition after chemo Ureteral obstruction

Editor's Notes

  1. Endometrial cancer is the MOSt common malignancy of the female genital tract. It usually shows itself early by irregular, persistent bleeding. IT progresses through a series of changes from normal to hyperplasia to cancer over time, thus allowing earlier diagnosis, intervention, and overall a good prognosis.
  2. Average age is 60 y/o. The most common cause is persistent ,prolonged estrogen exposure with out adequate progesterone opposition. It begins as cells slowly change from normal , becoming hyperplastic (Too thick- too many cells), less organized (complex hyperplasia), more and more atypical cells, and ultimately cancerous. Because each gland reacts to the estrogen stimulation at differing rates, there may be several levels of abnormality in the same uterus at the same time ( i.e.- normal cells, next to complex hyperplasia, with some areas of early carcinoma).90% of endometrial cancers are endometrioid cell types, which are lower grade and have a good prognosis.About 10% are more papillary serous cell types which behave much more aggressively and are the cause of most recurrences. Clear cell and MMT are rare types with extremely poor prognosis.
  3. Let’s talk about risk factors. The endometrium is normally under the influence of estrogen from menarche to menopause, predominantly in the follicular phase (proliferative phase) or first half of the menstrual cycle. The more exposure to estrogen, the more proliferation of the endometrium occurs. When the uterus never gets a break from this stimulation (infertility, nulliparity) endometrial cancer is more likely to occur.With increased BMI comes increased estrogen stimulation due to the aromatization of circulating precursors into estrogens in the fat cells. Thus, higher incidence of endometrial ca. If that chronically elevated estrogen level causes infrequent / inconsistent ovulation by negative Pituitary feedback, menses become irregular, endometrial build-up is more likely and the progression from normal&gt; hyperplasia&gt; cancer begins.All of this takes time. It doesn’t happen in a few cycles. So a woman who started menses early, finished late, had a more years of irreg menses is more likely to develop endo ca.Genetics- There is also an increased risk for families with nonpolyposis colorectal cancer. Actually a 40-60% lifetime risk of endometrial Ca for women in these families.
  4. What risk factors did you hear her name? One that she alluded to is her weight. She is 5 ft tall and at the time of diagnosis was 296LB. It isn’t unusual for women who are self-conscious of their weight to avoid seeking medical care. It’s also not unusual for women to think “This is menopause. It will surely go away soon.” Busy with life, time gets away from them and before they know it, a few months of irreg bldg with occ gushes has turned into too many month and things have progressed.
  5. There is no screening test. At routine physical or yearly Gyn exam, there will be no physical findings. It is the bleeding pattern that you must listen for. Is this a normal time in her life to to bldg? (Certainly if she had gone a full year with no periods, she is menopausal and shouldn’t be bldg again.) Is it a normal pattern? A normal amount? Any time after aged 35-40, irregular bldg should alert you to the possibility of endometrial cancer. The more risk factors the patient has, the more you should be concerned.Once your index of suspicion has been raised, you need TISSUE to know for sure.Let’s have a word about US. US will tell you shape and size of the uterus. OVERALL,this isn’t helpful in diagnosis. HOWEVER, in a menopausal woman who doesn’t have estrogen stimulating her endometrium, the endometrium should be very thin. The endometrial thickness CAN be measured on US&gt; We know that cancer has almost never been found in an endometrium measuri ng less than or equal to 4mm . This is the one use of US in this disease. If an elderly woman comes in bleeding and US reveal s endometrial stripe &lt;= 4mm, she doesn’t need a biopsy or treatment, just f/u.
  6. How did she describe her bldg pattern? Is this a normal cycle? What risk factors did she have? What about age? Would you expect at age 58 that she would still be bldg? Part of the confusion for Mrs T arose from the fact that she kept waiting for menopausal symptoms. Since she never hot flashed and never had an extended period with no bldg, it took longer for her to realize something was amiss.
  7. A packet is available with an aspiration biopsy device used to get a sample of endometrial cells. In the packet are directions for a short lab to practice using it and a YouTube site showing a 2 minute video to watch before trying. This can be done in the office. Most of the time, the pathology on your sample with be consistent with what a full pathology specimen would reveal, thus making it a good office approach to diagnosis.However, there are times where the cervix is too stenosed to get through,or where the pathologist tells you that not enough specimen was obtained to give you a reliable answer as to whether or not there is cancer. Then you must proceed or refer for D&amp;C to get a sample. This is still a diagnostic procedure NOT a treatment. Even with adequate tissue on D&amp;C, invasive lesions can be missed. The only complete diagnosis can be gotten when the entire uterus in “in the pan”. Therefore , if your biopsy is negative but the patient continues to bleed, keep looking!
  8. Let ‘s talk about US. Though no kind of imaging will give a tissue diagnosis, US does have a place in the diagnosis of endometrial ca. With US the thickness of the endometrium can be accurately measured. This is used in infertility to see if the lining is adequately prepared for implantation. If the endometrial width is within normal limits, an endometrial mass such as a polyp or fibroid isn’t likely. AND in a postmenopausal female we know that an endometrial stripe (thickness) of less than or equal to 4mm is extremely unlikely to harbor endometrial cancer. Therefore, an US report showing &lt;= 4mm of endometrium in a menopausal woman allows us to safely watch and not biopsy.
  9. Endometrial cancer starts a specific area – usually the glands of the endometrium. It grows locally, working it’s way through the endometrium. The further it gets through the endometrium, the increased likelihood disease extending to the ovaries, getting into the pelvic lymph nodes and then to the the periaortic nodes. This readily demonstrated by going to the above web site under the diagnosis and staging section then scrolling down to the pictures of stages. Keep clicking and you’ll watch the progression. Knowing how it behaves allows adequate treatment and appropriate follow-up.
  10. If your pathology shows that the tissues is not fully cancerous yet (hyperplasia, complex hyperplasia, even atypical hyperplasia if fertility is to be retained) &gt; progestational agents can be used to reverse the process. Close follow-up of the tissue must be maintained. For endometrial cancer, treatment is based on staging. Staging is surgical. How far does it go through the endometrium? Is it in pelvic lymph nodes? Periaortic nodes? If the disease is Stage 1 (based on surgical staging), post-operative radiation doesn’t improve survival.For any with disease beyond stage I, radiation therapy is the next step.
  11. Prognosis for the endometrioid cell type ( 90% - 95% of all endometrial Ca) is good. She will continue to live after adequate treatment , to have to deal with the other issues of obesity and prolonged estrogen stimulation. The earlier it’s found, the easier to treat (Remember stage 1 is completely treated after the surgical staging hysterectomy!) Follow-up is fairly simple – several visits to the Gyn Oncologist for pelvic exams only.Rare cell types are much more likely to recur and are less responsive to radiation therapy from the onset.
  12. In review, to find and treat endometrial cancer, you must listen for the clues. Is this patient at risk? Does she have prolonged estrogen exposure either endogenous or exogenous? Has she described bleeding to you that isn’t normal? Has it gone on long enough (is she old enough) to warrant concern for the status of her endometrium. Remember: there is no way other way to screen for this. Nothing for look for on routine exam. No xrays or labs to order. Endometrial biospy is the beginning of diagnosis for what can be a very successful cancer story.